ASPHALION’s Post

The potential of cyclodextrins in addressing age-related issues, particularly in longevity and heart health, is a promising area of research. Cyclodextrins, cyclic oligosaccharides, have shown potential in various biomedical applications, including drug delivery and cholesterol management. Matthew "Oki" O'Connor, CEO of Cyclarity Therapeutics, is exploring the impact of cholesterol on aging and the potential of cyclodextrins to address age-related issues. O'Connor's work is shedding light on the role of cholesterol in aging and the potential of cyclodextrins to improve healthspan and extend lifespan. Join us at Longevity Summit Dublin from June 13-16, 2024, to learn more about the latest developments in this field and connect with leading researchers, investors, and industry professionals. The summit will feature talks and networking opportunities, allowing attendees to learn about the latest developments and connect with experts in the field.   June 13-16, 2024 Dublin, Ireland Reserve your tickets at https://lnkd.in/dfbxP2Jy #Cyclodextrins #Longevity #AntiAging #Healthspan #Cholesterol #CyclarityTherapeutics #LongevitySummitDublin #levfoundation Matthew "Oki" O'Connor Aubrey de Grey Longevity Escape Velocity (LEV) Foundation Martin O 'Dea

📣 We are thrilled to announce the launch of our new Cilia Beat Frequency analysis assay for lung small airway epithelium cells (SAEC). This cutting-edge software enables researchers to assess the effect of drugs and chemicals on the function of cilia. The new, functionally-validated assay generates reliable and predictive in vitro data on the activity of the beating cilia of the airways. It allows the assessment of dosing on mucus clearance, the function of cilia, and evaluation of drug efficacy in reversing disease-like conditions. Unlock a comprehensive, high-sensitivity set of data that accurately measures the effect of your compound, including fast-acting ones, on mucociliary clearance. Dr Dr Mike Nicholds, CEO and Co-Founder, Newcells Biotech, commented: “CiliaBeat complements our existing capabilities, giving customers more options to gain physiologically-relevant insights into this crucial organ type.” Amy Mawdesley, Account Manager, is on hand at the European Respiratory Society in Vienna to answer your questions about CiliaBeat! Find out more here: https://lnkd.in/extRdN2R #Newcells #LungAssay #Cilia #SAEC

Excited to share a recent success story from our team at TruLab! Challenge Faced: During a critical Phase 1/2 study of a new therapy for a neurological disease lacking FDA-approved treatments, our client faced significant hurdles. Over 100 samples were lost at the first European site, jeopardizing the entire study. TruLab’s Intervention: When the study's progress stalled due to sample losses and data discrepancies, the sponsor turned to us. We swiftly implemented our study-specific app and conducted on-site training, providing the tools needed to enhance visibility and control over site activities. With TruLab's solutions: 📈 Zero samples were lost among ~5,000 collected from the new cohorts. 📉 Queries dropped from hundreds to zero, streamlining data management. 🌍 The study expanded, thanks to reliable, clean sample data. This engagement highlights the power of real-time insights and proactive management in clinical research. We're proud to have enabled our client to not only continue but also expand their study, potentially bringing a new treatment to the market. Download the case study here: https://trulab.com/rescue/ Contact us to learn more about how we can help your studies: https://lnkd.in/dtZDB2wi #ClinicalTrials #Biotechnology #PharmaIndustry #Innovation #CaseStudy

📢 Join SynapCell at the EILAT XVII Conference in Madrid, Spain, from May 5 to 8, 2024! Corinne Roucard, CEO of SynapCell, will be presenting a poster entitled "Differential Profile of Anti-seizure Medications in the Rat Amygdala-Kindling Model", exploring how the translational aspects of the kindled amygdala in the rat are enabling the identification of new compounds with improved tolerance and efficacy on focal and secondarily generalized seizures. The combination of this model and a cross-over design empower our decision-enabling testing platform to identify novel compounds for the prevention, treatment, and modification of #epilepsy, wherein pharmacoresistant focal seizures constitute the greatest challenge for treatment. 👉For more information and set a meeting, please contact Corinne Roucard. 👉Read the abstract: https://lnkd.in/eQh2Mejp #eilatconference #epilepsy #EEG

📹BETWEEN THE LINES: Raj Chovatiya, MD, PhD, MSCI; and Christopher Bunick, MD, PhD, analyze clinical trial data, compare treatment efficacies of upadacitinib and dupilumab, evaluate quality of life measures, and emphasize the importance of translating study results into real-world atopic dermatitis management strategies. Discover expert insights on treatment efficacy and real-world application: https://ow.ly/SyWl50TnjMt

Excited to share my latest publication in Journal of Drug Delivery Science and Technology with an impact factor of 5 In this review, I delve into the fascinating world of transferosomes, exploring their potential as game-changers in antifungal therapy. From their unique structure to their promising applications, this comprehensive analysis sheds light on how these innovative drug delivery systems could revolutionize treatment strategies for fungal infections. 🔍 Want to learn more? Dive into the full article here [https://lnkd.in/gRpsJzAS] and let's spark a conversation about the future of antifungal therapy! 💬 #DrugDelivery #AntifungalTherapy #Transferosomes #MedicalResearch #Innovation

In this article, Dr. Wilhelm Graf et al. highlight the efficacy of NASHA/Dx for the treatment of fecal incontinence. Read it here: https://ow.ly/EC0f50QRpY5 For more clinical articles and educational resources, visit https://ow.ly/a9b750QRpY4 Reference: 1. Graf W, Mellgren KE, et al; for NASHA Dx Study Group. Efficacy of dextranomer in stabilised hyaluronic acid for treatment of faecal incontinence: a randomised, sham-controlled trial. Lancet. 2011;377(9770):997-1003. #BI #continencematters #Solesta

When dynamic leadership meets cutting-edge innovation, companies are able to ignite change, solve pressing problems, and improve lives. This is what is happening at CytoAgents. CEO Teresa Whalen, RPh is leading a team of world-renowned clinical drug development experts and scientific advisory board members who are at the forefront of a groundbreaking treatment of life-threatening symptoms associated with Cytokine Release Syndrome (CRS), an overreaction of the immune system causing systemic inflammation. Follow our journey here: https://cytoagents.com/ #biotechnology #biotech #biotechleadership #cytokinereleasesyndrome #crs

We’re excited to share a major development at AGYANY Pharma, founded by Professor Ari ZIMRAN in November 2022. With decades of expertise in Gaucher Disease, Prof. Zimran is leading the charge to advance the treatment of GBA1-associated Parkinson’s Disease (GBA1-PD) through pioneering clinical trials with pharmacological chaperones like Ambroxol. Our mission extends beyond generating crucial data for future therapies. We are committed to developing innovative treatments that could transform the care landscape for both Gaucher Disease and GBA1-PD. Recently, we secured key patents for the use of Ambroxol in treating these conditions—a pivotal moment in our journey. Our vision is clear: to deliver the first safe and effective therapies for these devastating diseases, meeting the most pressing needs of patients and setting a new standard in care. #Biotech #HealthcareInnovation #GaucherDisease #ParkinsonsDisease #MedicalResearch

We are thrilled to be presenting data on the clinical progress with our masked anti-CTLA-4 ADG126 plus pembrolizumab at this year’s ESMO! Tune in for the latest results with this IO doublet in 3L MSS CRC, including data at the 10 mg/kg Q3W dose in a larger patient cohort! The poster will report results of an ongoing phase 1b/2 trial of Adagene’s masked anti-CTLA-4 SAFEbody in combination with the anti-PD-1 treatment pembrolizumab. The title is: Increased Therapeutic Index of Muzastotug (Muza, ADG126), a Masked Anti-CTLA-4 SAFEbody®, in Combination with Pembrolizumab (Pembro) Enables Significant Clinical Benefits and Supports Further Clinical Development in Patients with Metastatic MSS CRC #Adagene #innovation #treatment #clinicalprogress https://loom.ly/KHCaYp8